Assessment of Disease Awareness, Medication Utilization and Antibiotics-Associate Risk of Ibd Patients: A Survey-Base Study

Inflammatory bowel disease (IBD) is rising occurrences among young people because it needs better awareness and improved diagnostic methods and effective treatment approaches. The current population survey-based study aimed to evaluate demographic characteristics, disease prevalence, treatment patterns, antibiotic use, and patient behaviour regarding drug interactions among individuals. The study results demonstrated that most test subjects belonged to the age group of 20 to 29 years while the second largest group included people aged 10 to 19 years which proved that young people face the highest risk of potential danger. While most respondents reported not being diagnosed with IBD, a small proportion confirmed having the disease, and a notable percentage remained uncertain, highlighting gaps in awareness and diagnostic clarity. IBD patients who had received a diagnosis used different types of medications because personal treatment plans required them to use multiple drugs including immunosuppressants and biologics and anti-inflammatory drugs. More than half of the participants from the survey reported that they had used antibiotics during the previous twelve months which created worries about how this practice might affect their gut microbiome and lead to worse health outcomes. Although many participants did not experience noticeable side effects from concurrent use of antibiotics and IBD medications, some reported adverse effects including gastrointestinal, respiratory, and dermatological symptoms. The majority of respondents failed to tell their doctors about possible drug interactions which created a major communication gap between patients and their doctors. The base on survey that IBD has low diagnosed rates but research shows that people lack knowledge of the disease and its early identification and the methods to manage it. The improvement of treatment results together with safer IBD management requires three essential components which include better patient education and the establishment of sensible medication practices and the development of effective drug safety monitoring systems.